alogliptin

アログリプチン


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/07/19 19:00:46」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

  • Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
  • Bosi E, Ellis GC, Wilson CA, Fleck PR.SourceDepartment of Internal Medicine, Diabetes & Endocrinology Unit, San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy. bosi.emanuele@hsr.it
  • Diabetes, obesity & metabolism.Diabetes Obes Metab.2011 Dec;13(12):1088-96. doi: 10.1111/j.1463-1326.2011.01463.x.
  • AIM: To assess the efficacy and safety of adding alogliptin versus uptitrating pioglitazone in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone.METHODS: In this randomized, double-blind, active-controlled, parallel-group study, patients with type 2 diabete
  • PMID 21733058
  • Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis.
  • Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S.SourceDavis Heart & Lung Research Institute, 473 W 12th Ave, Room 110, Columbus, OH 43210. sanjay.rajagopalan@osumc.edu.
  • Circulation.Circulation.2011 Nov 22;124(21):2338-49. Epub 2011 Oct 17.
  • Background- Dipeptidyl-peptidase 4 (DPP-4) inhibitors are increasingly used to accomplish glycemic targets in patients with type II diabetes mellitus. Because DPP-4 is expressed in inflammatory cells, we hypothesized that its inhibition will exert favorable effects in atherosclerosis. Methods and R
  • PMID 22007077

Japanese Journal

  • 高選択的DPP-4阻害薬アログリプチン安息香酸塩(ネシーナ^【○!R】錠)の薬理作用および臨床効果
  • 武内 浩二,藤田 哲也,廣居 伸蔵
  • 日本薬理学雑誌 137(1), 43-50, 2011-01-01
  • 高選択的DPP-4阻害薬アログリプチン安息香酸塩(ネシーナ®錠)は2型糖尿病に対する治療薬である.アログリプチンは医薬分子構造設計(SBDD)技術を駆使して創製され,DPP-4の活性部位と共有結合は形成せず,静電相互作用,水素結合,π-πスタッキングなどの種々の相互作用をバランス良く,かつ効率的に利用することにより,DPP-4選択的に強力に結合する.2型糖尿病モデル動物において,アログリ …
  • NAID 10027747338
  • 症例報告 アログリプチンとボグリボースの併用効果を持続血糖モニターで確認できた1例
  • 森 博子,岡田 洋右,黒住 旭 [他]
  • 糖尿病 54(6), 425-429, 2011-06
  • NAID 40018920118

Related Links

Alogliptin (codenamed SYR-322) is an orally administered, anti-diabetic drug in the DPP-4 inhibitor class, developed by ... A randomized clinical trial reporting in 2011 aimed to determine the efficacy and safety of alogliptin versus placebo and ...


Related Pictures

Generic Name and Formulations:Nesina (alogliptin) for type 2 diabetesAlogliptinThe image above shows a crystal structure File:Alogliptin.svgполучить увеличенное



★リンクテーブル★
リンク元アログリプチン

アログリプチン」

  [★]

alogliptin
ネシーナ
ジペプチジルペプチダーゼ4阻害薬